Conversion Ratio. The “Conversion Ratio” for each share of Series B Preferred Stock shall be equal to the Stated Value divided by the Conversion Price.
Appears in 4 contracts
Sources: 3(a)(9) Exchange Agreement (Pieris Pharmaceuticals, Inc.), Securities Exchange Agreement (Oncothyreon Inc.), Loan and Security Agreement (Cytokinetics Inc)
Conversion Ratio. The “Conversion Ratio” for each share of Series B A Preferred Stock shall be equal to the Stated Value divided by the Conversion Price.
Appears in 4 contracts
Sources: 3(a)(9) Exchange Agreement (Cullinan Oncology, Inc.), 3(a)(9) Exchange Agreement (Verastem, Inc.), Underwriting Agreement (Molecular Templates, Inc.)
Conversion Ratio. The “Conversion Ratio” for each share of Series B C Preferred Stock shall be equal to the Stated Value divided by the Conversion Price.
Appears in 3 contracts
Sources: Securities Purchase Agreement (T2 Biosystems, Inc.), 3(a)(9) Exchange Agreement (Bain Capital Life Sciences Fund, L.P.), Securities Exchange Agreement (Oncothyreon Inc.)
Conversion Ratio. The “Conversion Ratio” for each share of Series B X Preferred Stock shall be equal to the Stated Value divided by the Conversion Price.
Appears in 2 contracts
Sources: Securities Purchase Agreement (Alpine Immune Sciences, Inc.), 3(a)(9) Exchange Agreement (Cidara Therapeutics, Inc.)
Conversion Ratio. The “Conversion Ratio” for each share of Series B Y Preferred Stock shall be equal to the Stated Value divided by the Conversion Price.
Appears in 2 contracts
Sources: Investment Agreement (Biotechnology Value Fund L P), Investment Agreement (XOMA Corp)
Conversion Ratio. The “Conversion Ratio” for each share of Series B C-1 Preferred Stock shall be equal to the Stated Value divided by the Conversion Price.
Appears in 1 contract
Conversion Ratio. The “Conversion Ratio” for each share of Series B D Preferred Stock shall be equal to the Stated Value divided by the Conversion Price.
Appears in 1 contract
Sources: Placement Agent Agreement (Cascadian Therapeutics, Inc.)
Conversion Ratio. The “Conversion Ratio” for each share of Series B E Preferred Stock shall be equal to the Stated Value divided by the Conversion Price.
Appears in 1 contract
Sources: Underwriting Agreement (Cascadian Therapeutics, Inc.)